{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay with the electrochemiluminescence detection technology.","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Participants with available post-baseline antibody results","reportingStatus":"POSTED","timeFrame":"Day 29 of each treatment period and 30 days after the last dose","title":"Number of Participants Who Developed Anti-blinatumomab Antibodies","type":"SECONDARY","unitOfMeasure":"participants"}